OBJECTIVES: Giant cell arteritis (GCA) is a chronic systemic vasculitis of large and medium-sized arteries, for which long-term glucocorticoid (GC) treatment is needed. During GC withdrawal patients can suffer adrenal insufficiency. We sought to determine the time until recovery of adrenal function after long-term GC therapy, and to assess the prevalence and predictors for secondary adrenal insufficiency. SUBJECTS AND DESIGN: 150 patients meeting the ACR criteria for GCA between 1984 and 2012 were analyzed. All received the same GC treatment protocol. The low-dose ACTH stimulation test was repeated annually until adrenal recovery. Biographical, clinical and laboratory data were collected prospectively and compared. RESULTS: At the first ACT...
Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydroc...
Objective: Glucocorticoids (GC) are associated with side effects in giant cell arteritis (GCA). Immu...
Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydroc...
Objectives: Giant cell arteritis (GCA) is a chronic systemic vasculitis of large and medium-sized ar...
Objective Patients with rheumatic diseases are often treated with prolonged, high-dose systemic glu...
OBJECTIVE: To evaluate the frequency of long-term remission after glucocorticoids (GCs) suspension i...
BackgroundThe chronic use of glucocorticoids (GC) suppresses function of the hypothalamic-pituitary-...
Purpose:The predictive factors of adrenal insufficiency after a prolonged, continuous course of cort...
Giant cell arteritis is usually a self-limiting disease with a variable duration of months to years....
BackgroundBiochemical adrenal insufficiency induced by glucocorticoid treatment is prevalent, but da...
AbstractObjectivesThe aim of this systematic literature review was to summarize the current knowledg...
Abstract: Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therap...
Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impa...
Context: Successful tumor resection in endogenous Cushing's syndrome (CS) results in tertiary adrena...
Context: Contrary to current dogma, growing evidence suggests that some patients with autoimmune Add...
Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydroc...
Objective: Glucocorticoids (GC) are associated with side effects in giant cell arteritis (GCA). Immu...
Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydroc...
Objectives: Giant cell arteritis (GCA) is a chronic systemic vasculitis of large and medium-sized ar...
Objective Patients with rheumatic diseases are often treated with prolonged, high-dose systemic glu...
OBJECTIVE: To evaluate the frequency of long-term remission after glucocorticoids (GCs) suspension i...
BackgroundThe chronic use of glucocorticoids (GC) suppresses function of the hypothalamic-pituitary-...
Purpose:The predictive factors of adrenal insufficiency after a prolonged, continuous course of cort...
Giant cell arteritis is usually a self-limiting disease with a variable duration of months to years....
BackgroundBiochemical adrenal insufficiency induced by glucocorticoid treatment is prevalent, but da...
AbstractObjectivesThe aim of this systematic literature review was to summarize the current knowledg...
Abstract: Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therap...
Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impa...
Context: Successful tumor resection in endogenous Cushing's syndrome (CS) results in tertiary adrena...
Context: Contrary to current dogma, growing evidence suggests that some patients with autoimmune Add...
Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydroc...
Objective: Glucocorticoids (GC) are associated with side effects in giant cell arteritis (GCA). Immu...
Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydroc...